UniProtKB/Swiss-Prot P21802 : Variant p.Ala344Gly
Fibroblast growth factor receptor 2
Gene: FGFR2
Feedback ?
Variant information
Variant position:
344
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Alanine (A) to Glycine (G) at position 344 (A344G, p.Ala344Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and hydrophobic (A) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CS and JWS.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
344
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
821
The length of the canonical sequence.
Location on the sequence:
IEVLYIRNVTFEDAGEYTCL
A GNSIGISFHSAWLTVLPAPG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human IEVLYIRNVTFEDAGEYTCLA GNSIGISFHSAWLTVLPAPG
Mouse IEVLYIRNVTFEDAGEYTCLA GNSIGISFHSAWLTVLPAPV
Chicken IEVLYIRNVTFEDAGEYTCLA GNSIGISFHTAWLTVLPAPE
Xenopus laevis IEVLYVRNVSFEDAGEYTCIA GNSIGISQHSAWLTVHPAPV
Zebrafish IEVLYLPNVTFEDAGEYTCLA GNSIGISYHTAWLTVHPAET
Drosophila V-VLTLRNVTFDQEGWYTCLA SSGLGRSNSSVYLRVV-SPL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 821
Fibroblast growth factor receptor 2
Topological domain
22 – 377
Extracellular
Domain
256 – 358
Ig-like C2-type 3
Glycosylation
331 – 331
N-linked (GlcNAc...) asparagine
Alternative sequence
250 – 361
Missing. In isoform 17.
Alternative sequence
255 – 821
Missing. In isoform 8.
Alternative sequence
314 – 429
Missing. In isoform 9.
Alternative sequence
341 – 353
TCLAGNSIGISFH -> ICKVSNYIGQANQ. In isoform 3, isoform 4, isoform 11, isoform 12, isoform 13 and isoform 16.
Alternative sequence
361 – 361
P -> PKQQ. In isoform 3, isoform 4, isoform 11, isoform 12, isoform 13 and isoform 16.
Beta strand
338 – 346
Literature citations
Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome.
Gorry M.C.; Preston R.A.; White G.J.; Zhang Y.; Singhal V.K.; Losken H.W.; Parker M.G.; Nwokoro N.A.; Post J.C.; Ehrlich G.D.;
Hum. Mol. Genet. 4:1387-1390(1995)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361; VARIANTS CS PRO-289; ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354;
Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.
Jabs E.W.; Li X.; Scott A.F.; Meyers G.A.; Chen W.; Eccles M.; Mao J.; Charnas L.R.; Jackson C.E.; Jaye M.;
Nat. Genet. 8:275-279(1994)
Cited for: VARIANTS CS CYS-328 AND CYS-347; VARIANT JWS GLY-344;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.